Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Contingent Consideration (Details)

v3.24.2.u1
Commitments and Contingencies - Contingent Consideration (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Jan. 11, 2024
Jun. 21, 2023
Mar. 29, 2023
Oct. 06, 2021
Jun. 30, 2023
Mar. 31, 2024
Jun. 30, 2024
Jun. 30, 2023
Jun. 03, 2024
Dec. 31, 2023
Commitments And Contingencies                    
Contingent consideration under RPAs, AAAs and CPPAs             $ 3,000,000     $ 7,000,000
Exarafenib milestone contingent consideration             2,922,000      
Payments of consideration under RPAs, AAAs and CPPAs             37,000,000 $ 14,650,000    
Changes in estimated fair value of contingent consideration               $ 75,000    
Short-term royalty and commercial payment receivables             14,257,000     14,215,000
Long-term royalty and commercial payment receivables             69,731,000     57,952,000
Kinnate                    
Commitments And Contingencies                    
Exarafenib milestone contingent consideration             2,900,000      
Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx                    
Commitments And Contingencies                    
Payments of consideration under RPAs, AAAs and CPPAs   $ 5,000,000.0                
Assignment and Assumption Agreement and Royalty Purchase Agreement | LadRx | Regulatory milestones                    
Commitments And Contingencies                    
Contingent consideration under RPAs, AAAs and CPPAs   $ 1,000,000.0       $ 0 0   $ 0 1,000,000.0
Payments of consideration under RPAs, AAAs and CPPAs $ 1,000,000.0         1,000,000.0 1,000,000.0      
Commercial Payment Purchase Agreement | Aptevo                    
Commitments And Contingencies                    
Contingent consideration under RPAs, AAAs and CPPAs     $ 50,000              
Payments of consideration under RPAs, AAAs and CPPAs     $ 9,600,000   $ 50,000          
Short-term royalty and commercial payment receivables             1,900,000     2,000,000.0
Commercial Payment Purchase Agreement | Affitech                    
Commitments And Contingencies                    
Payments of consideration under RPAs, AAAs and CPPAs       $ 6,000,000.0   6,000,000.0        
Commercial Payment Purchase Agreement | Affitech | Regulatory milestones                    
Commitments And Contingencies                    
Contingent consideration under RPAs, AAAs and CPPAs       $ 8,000,000.0            
Commercial Payment Purchase Agreement | Affitech | Sales-based milestones, first and second                    
Commitments And Contingencies                    
Contingent consideration under RPAs, AAAs and CPPAs           0 $ 0     6,000,000.0
Long-term royalty and commercial payment receivables                   $ 6,000,000.0
Commercial Payment Purchase Agreement | Affitech | Sales-based milestones, third                    
Commitments And Contingencies                    
Contingent consideration under RPAs, AAAs and CPPAs           3,000,000.0        
Short-term royalty and commercial payment receivables           $ 3,000,000.0